alexa Abstract | Study of Imatinib Mesylate Treated Patients sufferening from Chronic Myeloid Leukemia

Asian Journal of Biomedical and Pharmaceutical Sciences
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)


Chronic Myeloid Leukemia (CML) is also an attractive target for a rationally designed drug development programme and it was probably the first form of leukemia to be recognized as a distinct entity. In our present follow up study, taken normal healthy individuals, Interferon alpha, Hydroxyurea, Imatinib mesylate treated patient. The percentage response rate of interferon was 90% in which 10% have shown complete response, 30% with partial response and 50% with stable condition. The response rates in patients treated with Imatinib mesylate have shown 87.5%. The overall major cytogenetic response (MCR) was 2.5%, Complete cytogenetic response (CCR) was 77.5% and 7.5% in stable condition. This clearly demonstrates that Indian patients respond to this drug better than their foreign counter parts. This may be due to multiple reasons including food, cultural and geographical conditions. Indian people are known for more consumption of the species. Their food ingredients may be expected to be viding better health surveillance. The most notable finding was transformation of the accelerated phase and into the chronic phase in some patients. This follow up study supports the global view that the therapy with Imatinib mesylate may be continued unless resistance against it develops and it should be considered as the drug of first choice in CML.

To read the full article Peer-reviewed Article PDF image

Author(s): Amit K Dutta N Ganesh N K Sah A Vani


Chronic myeloid leukemia, Imatinib mesylate induction, Blood Culture, Follow up Study

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

1-702-714-7001Extn: 9037

Business & Management Journals


1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

1-702-714-7001 Extn: 9042

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version